SYNERGY Research

End-to-End Pharmacovigilance Service Provider
Locations
Mahwah, NJ
Washington, DC
Stroudsburg, PA
Honolulu, HI

DISCOVERY | RESEARCH | MONITOR | DATA SAFETY

Pharmacovigilance Solutions
  • Serious Adverse Event (SAE) /SUSARs management

  • Adverse Event (AE) data intake

  • Secure, accurate, and timely case entry and evaluation into validated safety database

  • Coding (MedDRA, WHO Drug)

  • Safety database

  • Annual safety reports and DSURs

  • Medical Review

  • Patient Event narrative

  • Regulatory Support and Intelligence

  • Literature Search Services

  • Report via Eudravigilance

  • Safety Medical Writing

  • Medical Information Support

 
Coronavirus disease (COVID-2019) R&D

On 31 December 2019, WHO was informed of a cluster of cases of pneumonia of unknown cause detected in Wuhan City, Hubei Province of China. The coronavirus disease (COVID-2019) was identified as the causative virus by Chinese authorities on 7 January. As part of WHO’s response to the outbreak, the R&D Blueprint has been activated to accelerate diagnostics, vaccines and therapeutics for this novel coronavirus. Read more...

Coronavirus_H2.jpg
Covid1.gif

Biopharmaceutical industry leads the way in making diagnostics kits, developing new vaccines and treatments to contain COVID-19

Nearly 80 clinical trials for experimental new treatments and vaccines in development for coronaviruses including COVID-19, Novel Coronavirus Pneumonia, SARS and MERS.